FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

James Koprich

Chief Technology Officer Kunming Biomed International (KBI)

Thursday 5th February 2026

Kunming Biomed International – CRO Services for CNS Oriented NHP Studies

11:40 am

Modeling of PD and AD pathology in macaques for therapeutic efficacy testing
MRI and PET imaging capabilities related to pathology and efficacy endpoints
Biodistribution study designs with CNS dosing, biomarker quantification, safety/pathology and pharmacodynamic readouts
Behavior and cognitive assessment capabilities